Oculis Holding AG
Oculis Holding AG (OCS) Revenue
Annual & quarterly revenue history · segment & region breakdown
OCS · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsOculis Holding AG trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2020 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -100.00% |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare OCS revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Oculis Holding AG receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Oculis Holding AG reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CHF.
Data sourced from Oculis Holding AG's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
OCS revenue · 4 questionsOCS's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Oculis Holding AG SEC filings · GAAP · Oculis Holding AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026